Publication

Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status

Gijtenbeek, R. G. P., de Jong, K., Venmans, B. J. W., van Vollenhoven, F. H. M., Brinke, A. T., Van der Wekken, A. J. & van Geffen, W. H., 12-Aug-2019, In : Cochrane Database of Systematic Reviews. 2019, 8, 14 p., CD013382.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Gijtenbeek, R. G. P., de Jong, K., Venmans, B. J. W., van Vollenhoven, F. H. M., Brinke, A. T., Van der Wekken, A. J., & van Geffen, W. H. (2019). Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status. Cochrane Database of Systematic Reviews, 2019(8), [CD013382]. https://doi.org/10.1002/14651858.CD013382

Author

Gijtenbeek, Rolof G.P. ; de Jong, Kim ; Venmans, Ben J.W. ; van Vollenhoven, Femke H.M. ; Brinke, Anneke Ten ; Van der Wekken, Anthonie J. ; van Geffen, Wouter H. / Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status. In: Cochrane Database of Systematic Reviews. 2019 ; Vol. 2019, No. 8.

Harvard

Gijtenbeek, RGP, de Jong, K, Venmans, BJW, van Vollenhoven, FHM, Brinke, AT, Van der Wekken, AJ & van Geffen, WH 2019, 'Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status', Cochrane Database of Systematic Reviews, vol. 2019, no. 8, CD013382. https://doi.org/10.1002/14651858.CD013382

Standard

Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status. / Gijtenbeek, Rolof G.P.; de Jong, Kim; Venmans, Ben J.W.; van Vollenhoven, Femke H.M.; Brinke, Anneke Ten; Van der Wekken, Anthonie J.; van Geffen, Wouter H.

In: Cochrane Database of Systematic Reviews, Vol. 2019, No. 8, CD013382, 12.08.2019.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Gijtenbeek RGP, de Jong K, Venmans BJW, van Vollenhoven FHM, Brinke AT, Van der Wekken AJ et al. Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status. Cochrane Database of Systematic Reviews. 2019 Aug 12;2019(8). CD013382. https://doi.org/10.1002/14651858.CD013382


BibTeX

@article{59a8668e08124a4b8b62f04a23d7c615,
title = "Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status",
abstract = "This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To identify the best first-line therapy for advanced lung cancer in patients with performance status 2 without a targetable mutation or with an unknown mutation status.",
author = "Gijtenbeek, {Rolof G.P.} and {de Jong}, Kim and Venmans, {Ben J.W.} and {van Vollenhoven}, {Femke H.M.} and Brinke, {Anneke Ten} and {Van der Wekken}, {Anthonie J.} and {van Geffen}, {Wouter H.}",
year = "2019",
month = "8",
day = "12",
doi = "10.1002/14651858.CD013382",
language = "English",
volume = "2019",
journal = "Cochrane database of systematic reviews (Online)",
issn = "1469-493X",
publisher = "Wiley",
number = "8",

}

RIS

TY - JOUR

T1 - Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status

AU - Gijtenbeek, Rolof G.P.

AU - de Jong, Kim

AU - Venmans, Ben J.W.

AU - van Vollenhoven, Femke H.M.

AU - Brinke, Anneke Ten

AU - Van der Wekken, Anthonie J.

AU - van Geffen, Wouter H.

PY - 2019/8/12

Y1 - 2019/8/12

N2 - This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To identify the best first-line therapy for advanced lung cancer in patients with performance status 2 without a targetable mutation or with an unknown mutation status.

AB - This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To identify the best first-line therapy for advanced lung cancer in patients with performance status 2 without a targetable mutation or with an unknown mutation status.

U2 - 10.1002/14651858.CD013382

DO - 10.1002/14651858.CD013382

M3 - Article

VL - 2019

JO - Cochrane database of systematic reviews (Online)

JF - Cochrane database of systematic reviews (Online)

SN - 1469-493X

IS - 8

M1 - CD013382

ER -

ID: 112043908